Skip to content

    INFLUX

    INFLUX
    Healthcare·12 Nov 2025
    Management Summary

    Influx Healthtech reported strong H1 FY26 results with significant revenue and profit growth, driven by capacity expansions and diversification efforts across nutraceuticals, cosmetics, and ayurveda. The company is strategically investing IPO proceeds in new facilities and innovative product lines like nutritional beverages, while also expanding its global regulatory footprint. Management acknowledges minor delays in new facility commissioning due to weather and is addressing working capital efficiency.

    Highlights

    5
    • Revenue from operations grew 39% YoY to INR 66.8 crores in H1 FY26.

    • EBITDA increased 61% YoY to INR 14.7 crores, with margin expanding 302 bps to 22.0%.

    • PAT rose 78% YoY to INR 10 crores, with margin expanding 329 bps to 15.0%.

    • Several capacity expansion initiatives and operational upgrades were completed and are now fully operational.

    • The company remains debt-free with a cash surplus of INR 36.6 crores as of September 30, 2025.

    Concerns

    2
    • New facility completion is delayed by 1-1.5 months due to rains.

    • Debtor days were 113 days in March '25, influenced by a large client's raw material supply arrangement.

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue from Operations₹66.8 Cr+39%YoY
    2. 02EBITDA₹14.7 Cr+61%YoY
    3. 03EBITDA Margin22%
    4. 04PAT₹10 Cr+78%YoY
    5. 05PAT Margin15%

    Segment breakdown

    • Nutraceutical₹60.1 Cr90.0%
    • Cosmetics₹3.4 Cr5.1%
    • Ayurvedic Products₹2.7 Cr4.0%
    • Veterinary and Home Care₹0.6 Cr0.9%
    Donut· Share of Revenue

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹34 crores

    entirely through internal approvals and internal accruals, supplemented by IPO proceeds

    Debt

    Debt disclosed

    Liquidity

    Cash ₹36.6 crores

    Cash surplus includes INR 33.6 crores from IPO proceeds remaining in the bank, with INR 33 crores specifically placed in an RBI account.

    Guidance & targets

    12
    CategoryTargetPriority
    Revenue
    Business Doubling
    Double the business
    High
    Revenue
    Revenue Benchmark
    INR 450-500 Cr
    Medium
    Revenue
    FY26 Revenue Plan
    INR 150+ crores
    High
    Revenue
    H2 FY26 Revenue
    INR 80-82 crores
    High
    Revenue
    Topline Target
    INR 500 crores
    Medium
    Margin
    EBITDA Margin Sustainability
    Sustainable
    High
    Capacity
    Overall Capacity Increase
    2.5x to 3x
    High
    Capacity
    Pet Food Production Capacity
    10x increase
    High
    Capacity
    Beverage Line Capacity
    10,000 bottles per hour
    High
    Capacity
    H1 Capacity Expansion
    25%
    High
    Other
    Capex Revenue Generation
    5-7 times of investment
    Medium
    Other
    Asset Turnovers
    5-6 times
    High

    New Nutraceutical/Veterinary Facility Operationalization

    H1 FY27
    Current1-1.5 month delay due to rains, orders placed for machinery
    TargetOperational by H1 FY27

    Why it matters

    Key for capacity expansion and achieving growth targets.

    H1 next year is our target to get everything in place. Maybe because of rains, we are 1-1.5 month behind, but we will cope up because we have already started to place orders and advances for the machineries, actually. So, we are on track, maybe by in H1, we should start next year that is FY26-FY27.

    How to verify

    capital_allocation.capex.purposes

    Risks & concerns

    3
    RiskSeverity

    Delay in new facility commissioning

    The new nutraceutical and veterinary facility is delayed by 1-1.5 months due to rains, pushing completion to H1 FY27.Management acknowledged

    medium

    High debtor days due to client-specific arrangement

    Debtor days were 113 days in March '25, primarily due to a strategic arrangement with a large client (Novus) where payment is made upon raw material utilization.Analyst acknowledged

    low

    Scaling management and operational team

    The company needs to build a larger and more robust team to manage operations as it scales towards a ₹500 crore revenue target.Analyst acknowledged

    medium

    Q&A highlights

    8

    “The idea is to focus on all the segments, because we don't want to be dependent on nutra. But over the years, nutra has done very well. So, we are known for that way and cosmetic, veterinary are very new. So, we will cope up, definitely. ... If you see, the margins are approximately gross margins are 35% in nutra, it will vary from product to product. But just for a brief knowledge, and cosmetic is much better.”

    Clarifies the strategic intent to diversify revenue streams and highlights the margin profile of different segments.

    asked by Jatin Agrawal

    3 min read6 chapters

    Detailed Narrative

    01

    H1 FY26 Financial Performance

    Influx Healthtech delivered a strong H1 FY26, with revenue from operations reaching INR 66.8 crores, marking a 39% year-on-year growth. EBITDA surged by 61% year-on-year to INR 14.7 crores, with margins expanding by 302 basis points to 22.0%. Net profit after tax (PAT) also saw robust growth, increasing by 78% year-on-year to INR 10 crores, and PAT margins improved by 329 basis points to 15.0%. The company maintains a healthy financial position with a cash surplus of INR 36.6 crores as of September 30, 2025.

    02

    Capacity Expansion and Operational Upgrades

    The company undertook several capacity expansion and operational upgrade initiatives during H1 FY26, entirely funded through internal approvals. Key expansions include tablet manufacturing capacity to 10,000-15,000 bottles per day with an investment of INR 60 lakhs, and a new high-speed capsule manufacturing line capable of 1,22,000 capsules per hour for INR 34.5 lakhs. Additionally, liquid production lines were added, and sachet production capacity increased to 32,000 per shift with a total investment of INR 1.91 crores. All these projects are now fully operational, enhancing production capabilities.

    03

    IPO Proceeds Utilization and New Facility Development

    Influx Healthtech has deployed INR 4.1 crores of its IPO proceeds towards capital expenditure, with INR 33.6 crores remaining in the bank for future investments. The company plans to utilize the remaining IPO funds to build a state-of-the-art nutraceutical and veterinary plant, with an estimated capex of INR 20-23 crores for nutra and INR 11 crores for veterinary. The target for this new facility to be in place is H1 FY27, though there has been a 1-1.5 month delay due to rains. Approximately INR 5-6 crores is planned for H2 FY26 for specific machinery like a retort plant and veterinary high-speed machines.

    04

    Segmental Growth and Diversification Strategy

    While nutraceuticals continue to be the largest segment, contributing INR 60.1 crores (36% YoY growth), Influx Healthtech is actively diversifying its revenue streams. The cosmetics segment grew significantly by 59% YoY to INR 3.4 crores, and ayurvedic products saw a substantial increase of 112% YoY to INR 2.7 crores. The veterinary and home care segment also reported a 20% YoY increase, reaching INR 0.6 crores. The company's strategy is to focus on all segments to reduce dependence on nutraceuticals, with cosmetics and veterinary expected to offer better margins as they scale.

    05

    New Market Entry and International Expansion

    The company is set to enter the beverage market with a new line capable of producing 10,000 bottles per hour, focusing on nutritional ready-to-drink (RTD) products. This initiative aims to tap into a new customer base and explore new market opportunities. Influx Healthtech is also expanding its global footprint, having secured FSSC 22000 certification from NSF International and US FDA registration, which opens doors to US and European markets. They are actively pursuing Tanzania approval, with an audit scheduled for December 11, 2025, to strengthen their presence in the African market.

    06

    Working Capital Management and Client Dynamics

    Influx Healthtech operates as a debt-free company with no short-term borrowings. Management addressed concerns regarding high debtor days (113 days in March '25), explaining it is a strategic arrangement with a major client, Novus Life Sciences, who supplies raw materials and is paid upon utilization. This unique model helps manage working capital efficiently by reducing the need for external funding. The company is continuously working to further improve its payment and receivable cycles.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.